A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers. by Johannes Vermehren, Jörn Lötsch, Simone Susser, Sabine Wicker, Annemarie Berger, Stefan Zeuzem, Christoph Sarrazin, Alexandra Doehring

Get full text

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. by Simone Susser, Eva Herrmann, Christian Lange, Nabila Hamdi, Tobias Müller, Thomas Berg, Dany Perner, Stefan Zeuzem, Christoph Sarrazin

Get full text

Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity. by Martin-Walter Welker, David Reichert, Simone Susser, Christoph Sarrazin, Yolanda Martinez, Eva Herrmann, Stefan Zeuzem, Albrecht Piiper, Bernd Kronenberger

Get full text

Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C InfectionSummary by Philipp Solbach, Sandra Westhaus, Maximilian Deest, Eva Herrmann, Thomas Berg, Michael P. Manns, Sandra Ciesek, Christoph Sarrazin, Thomas von Hahn

Get full text

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairm... by Christoph Sarrazin, Michael Manns, Jose Luis Calleja, Javier Garcia-Samaniego, Xavier Forns, Renee Kaste, Xiaofei Bai, Jing Wu, Jerry O Stern

Get full text

Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection. by Victoria Therese Mücke, Katja Jakobi, Viola Knop, Dominique Thomas, Marcus Maximilian Mücke, Kai-Henrik Peiffer, Stefan Zeuzem, Christoph Sarrazin, Josef Pfeilschifter, Georgios Grammatikos

Get full text

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab by Martin Heller, Clara Henrici, Judith Büttner, Sebastian Leube, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka Schanz, Agnes Hallier, Eva Herrmann, Michael Schmidt, Christoph Sarrazin

Get full text

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients by Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht

Get full text

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. by Bambang S Adiwijaya, Eva Herrmann, Brian Hare, Tara Kieffer, Chao Lin, Ann D Kwong, Varun Garg, John C R Randle, Christoph Sarrazin, Stefan Zeuzem, Paul R Caron

Get full text

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy by Viola Knop, Gerlinde Teuber, Hartwig Klinker, Bernd Möller, Jens Rasenack, Holger Hinrichsen, Tilman Gerlach, Ulrich Spengler, Peter Buggisch, Konrad Neumann, Christoph Sarrazin, Stefan Zeuzem, Thomas Berg

Get full text

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R) by Bernhard Schlevogt, Klaus H. W. Boeker, Stefan Mauss, Hartwig Klinker, Renate Heyne, Ralph Link, Karl-Georg Simon, Christoph Sarrazin, Yvonne Serfert, Michael P. Manns, Heiner Wedemeyer

Get full text

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. by Benjamin Maasoumy, Bela Hunyady, Vincenza Calvaruso, Mihály Makara, Johannes Vermehren, Attila Haragh, Simone Susser, Birgit Bremer, Gavin Cloherty, Michael P Manns, Antonio Craxì, Heiner Wedemeyer, Christoph Sarrazin

Get full text

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal by Christoph Sarrazin, Christoph Boesecke, Solmaz Golsabahi‐Broclawski, Gero Moog, Francesco Negro, Carmina Silaidos, Polly Patel, Kristina Lohmann, Christoph D. Spinner, Stephan Walcher, Heiner Wedemeyer, Marcus‐Alexander Wörns

Get full text

Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. by Georg Dultz, Martin Seelhof, Eva Herrmann, Martin-Walter Welker, Mireen Friedrich-Rust, Gerlinde Teuber, Bernd Kronenberger, Michael von Wagner, Johannes Vermehren, Christoph Sarrazin, Stefan Zeuzem, Wolf Peter Hofmann

Get full text

Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts by Victoria Therese Mücke, Janett Fischer, Marcus Maximilian Mücke, Alexander Teumer, Alexander Koch, Johannes Vermehren, Malin Fromme, Stefan Zeuzem, Christian Trautwein, Christoph Sarrazin, Thomas Berg, Biaohuan Zhou, Karim Hamesch

Get full text

PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. by Antoaneta A Markova, Ulrike Mihm, Verena Schlaphoff, Sebastian Lunemann, Natalie Filmann, Birgit Bremer, Thomas Berg, Christoph Sarrazin, Stefan Zeuzem, Michael P Manns, Markus Cornberg, Eva Herrmann, Heiner Wedemeyer

Get full text

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry by Frank Tacke, Hartwig Klinker, Klaus H. W. Boeker, Uta Merle, Ralph Link, Peter Buggisch, Dietrich Hüppe, Markus Cornberg, Christoph Sarrazin, Heiner Wedemeyer, Thomas Berg, Stefan Mauss, DHC‐R

Get full text

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. by Janett Fischer, Stephan Böhm, Tobias Müller, Heiko Witt, Christoph Sarrazin, Simone Susser, Pascal Migaud, Eckart Schott, Graeme Stewart, Annika Brodzinski, Balazs Fülöp, Florian van Bömmel, Jacob George, Thomas Berg

Get full text

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). by Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Robert Ryan, Oliver Lenz, Jane Scott, Gino Van Dooren, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti

Get full text

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure by Christiana Graf, Roberta D’Ambrosio, Elisabetta Degasperi, Stefania Paolucci, Jordi Llaneras, Johannes Vermehren, Georg Dultz, Kai-Henrik Peiffer, Fabian Finkelmeier, Eva Herrmann, Stefan Zeuzem, Maria Buti, Pietro Lampertico, Julia Dietz, Christoph Sarrazin

Get full text